TGA Therapeutic Goods Complete Guide for Taiwan Exporters

The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia under the Therapeutic Goods Act 1989. Any product making a therapeutic claim -- or meeting the functional definition of a therapeutic good -- must be included in the Australian Register of Therapeutic Goods (ARTG) before it can be legally imported, supplied, or advertised in Australia. For Taiwan exporters, this captures nutritional supplements, complementary medicines, topical analgesics, sunscreens above SPF 4, and over-the-counter medicines. Classification is determined by composition and claims, not by how the product is categorised in Taiwan.

A vitamin C supplement marketed as a health food in Taiwan becomes a listed complementary medicine in Australia the moment its packaging implies it supports immune function or reduces tiredness. The TGA's Product Regulation Decision Tool assesses products based on ingredients, dosage form, and label claims. Taiwan brands must run every product through this tool before accepting Australian purchase orders and document the outcome as part of their compliance file.

The consequences of supplying unregistered therapeutic goods include infringement notices of AUD 15,600 per violation for individuals and AUD 78,000 per violation for companies, product seizure at the border by Australian Border Force without compensation, and potential criminal referral. In 2023 the TGA took formal action against 47 companies for unlicensed supply, including several offshore manufacturers supplying through local distributors.

The TGA's jurisdiction extends to cross-border e-commerce. Each parcel shipped from Taiwan to an Australian consumer constitutes an importation event subject to TGA oversight. The AUD 1,000 low-value customs threshold applies only to GST -- it creates no exemption from TGA registration. Taiwan brands selling direct-to-consumer via Amazon Australia or Shopify with Australian customers must hold valid ARTG entries for every therapeutic good in their range.

The ARTG operates on a two-tier system. Listed medicines carry the AUST L designation and are self-assessed by the sponsor against TGA requirements. The sponsor certifies that all ingredients appear on the Permitted Ingredients list within permitted ranges, manufacturing is GMP-compliant, and evidence supports efficacy claims. The TGA does not conduct pre-market review of listed medicines; post-market audits verify compliance. The 2024-25 listing application fee is AUD 1,110 per product.

Registered medicines (AUST R) undergo full pre-market evaluation by TGA scientists before ARTG entry is granted. This category covers prescription medicines, higher-risk OTC medicines, and products making efficacy claims beyond the Permitted Indications list. Evaluation timelines are 12 to 30 months with fees from AUD 5,500 to AUD 90,000. For most Taiwan supplement and complementary medicine exporters, the listed medicine pathway is the appropriate starting point.

The Assessed Listed pathway (AUST L(A)) was introduced in 2018 for sponsors making specific health claims requiring evidence substantiation but not requiring full AUST R evaluation. Current processing time is 15 to 20 months with application fees around AUD 8,500. This pathway suits Taiwan brands making clinically substantiated mechanism claims -- such as a probiotic with an IBS symptom reduction claim -- that exceed general wellbeing thresholds.

Products outside therapeutic goods -- pure foods and cosmetics -- are regulated by different agencies. Food Standards Australia New Zealand (FSANZ) covers food products; AICIS covers industrial chemicals used in cosmetics. For borderline products, the TGA Product Regulation Decision Tool determines classification based on composition and claims. Taiwan brands should run every new product through this tool and retain the output before export.

Step 1: Appoint or become an Australian sponsor. The ARTG entry must be held by an Australian resident entity with an Australian Business Number (ABN). Taiwan manufacturers can establish an Australian Pty Ltd company (cost approximately AUD 1,000 plus ASIC fees) and act as their own sponsor, or appoint a third-party Australian contract sponsor. Contract sponsors charge AUD 3,000 to 8,000 per year plus per-product fees and assume regulatory liability for listed products.

Step 2: Create a TGA Business Services (TBS) account and complete the Sponsor Profile. The TBS portal is the single point of entry for all ARTG applications, Annual Charge payments, and post-market reporting. Complete the Certificate of Compliance confirming the sponsor understands regulatory obligations. Step 3: Prepare the product dossier including the full formulation, evidence that all ingredients are on the Permitted Ingredients list within permitted ranges, evidence for each indication claimed, a draft label complying with RASML, and a Quality Summary referencing the manufacturing site's GMP certification.

Step 4: Submit via TBS and pay the application fee. For standard AUST L, the TBS system guides sponsors through compliance declarations before generating the ARTG entry. Processing time is 5 to 10 business days for complete submissions. For Assessed Listed or Registered applications, submissions enter a formal evaluation queue with acknowledgement within 30 days and evaluation periods of 12 to 30 months.

Step 5: Ongoing compliance. Annual Charges of AUD 1,110 per ARTG entry are due each October; failure to pay results in automatic ARTG cancellation. Any product changes must be notified to the TGA within 30 days. Serious adverse events must be reported via the MedWatch Australia portal within 72 hours. Annual Performance Reports must be submitted through TBS confirming supply volumes and compliance status for each ARTG entry.

For standard AUST L listed medicines, the sponsor must hold evidence supporting each indication at the time of listing. The TGA does not require evidence submission upfront but requests the full dossier during post-market audits. If the sponsor cannot produce adequate evidence during audit, the TGA can require indication removal or cancel the ARTG entry -- a costly outcome after product launch.

The TGA's Evidence Guidelines for Listed Medicines (2023) classify evidence hierarchically. Level I (systematic reviews of RCTs) is required for specific claims about treatment, cure, diagnosis, or prevention of named conditions. Level II (individual well-designed RCT) supports claims about physiological outcomes. Level III and IV (non-randomised studies, expert opinion, traditional use) support general wellbeing statements such as 'supports healthy immune function.' Most Taiwan supplement brands target Level II or III evidence for core efficacy claims.

Traditional use claims -- based on documented use of an ingredient for at least 30 years -- provide an alternative pathway for Taiwan herbal products. The TGA accepts evidence from recognised reference texts including EU herbal monographs, German Commission E monographs, and established traditional Chinese medicine texts. Traditional use evidence supports only statements about historical use, not specific health outcome claims, and cannot be combined with modern clinical claims without additional evidence at the required level.

Taiwan manufacturers should ensure their studies use the same ingredient form, dose, and delivery route as the Australian product. A study using intravenous administration does not support an oral supplement claim. A regulatory consultant pre-assessment of your evidence package (cost AUD 3,000 to 8,000) before investing in ARTG application fees is strongly recommended. Consultants are available through Complementary Medicines Australia or the TGA regulatory consulting directory.

All ARTG-listed therapeutic goods must be manufactured in a facility holding valid GMP clearance issued by the TGA or by a recognised overseas regulatory authority. Taiwan's MOHW manufacturing audit certification is not on TGA's list of recognised overseas equivalents. Taiwan facilities must obtain a TGA GMP Clearance independently, or hold certification from the US FDA, EU GMP authority, or UK MHRA.

A TGA GMP Clearance for an overseas site requires submitting an application through TBS, paying the assessment fee (AUD 16,280 for desktop review or AUD 30,000+ for overseas inspection), and providing a recent GMP inspection report and Certificate of GMP Compliance from a competent authority. Taiwan manufacturers with current FDA registration have an advantage as FDA inspection records form a strong foundation for TGA applications. Processing time is 4 to 12 weeks for desktop assessments.

GMP Clearances are site-specific and product-category-specific. A clearance for solid dose complementary medicines does not cover liquid manufacturing at the same facility. Clearances are valid for 3 years and must be renewed before the ARTG entries they support can be lawfully supplied. Sponsors must notify the TGA within 30 days if the manufacturing site loses GMP standing.

Smaller Taiwan manufacturers without recognised GMP certification can use Australian contract manufacturers for final dose manufacturing while supplying active ingredients from Taiwan. Contract manufacturing adds AUD 2 to 5 per unit for solid dose complementary medicines at 50,000 to 100,000 unit volumes, but eliminates the GMP Clearance processing bottleneck and the AUD 16,000+ application cost.

Australian therapeutic goods labels are governed by the Therapeutic Goods (Labelling) Regulations 2002 and Required Advisory Statements for Medicine Labels (RASML). Every listed medicine label must display the ARTG number, name and address of the Australian sponsor, batch number and expiry date, directions for use, storage conditions, and all required RASML advisory statements. Minimum text size is 1.5mm x-height for most label content.

Permitted indications for AUST L listed medicines are drawn from the TGA's Permitted Indications database containing over 1,200 approved statement forms last updated in 2023. Claims outside this list -- disease-specific or comparative claims -- are prohibited on listed medicines. Taiwan brands should download the current Permitted Indications database from the TGA website before drafting any label copy.

RASML mandatory warnings apply when products contain specific ingredients. Products containing kava must carry a liver injury warning; products with willow bark require aspirin-related contraindication for children; products with caffeine above 100mg per dose must state the caffeine content. Labelling non-compliance is a separate TGA enforcement trigger from registration non-compliance.

Online listings on Amazon Australia and Shopify are treated as therapeutic goods advertising under the Therapeutic Goods Advertising Code 2021, with identical claims restrictions as physical labels. Product titles cannot claim a product 'cures' or 'treats' any condition. Advertising must reference only ARTG-listed indications and must include the required consumer advertising disclaimer specified in the Code.

TGA 2024-25 fee schedule: ARTG listing application fee AUD 1,110 per product; Annual Charge AUD 1,110 per ARTG entry per year. Assessed Listed application fee: AUD 8,460 with possible additional evaluation fees. Registered OTC medicines: evaluation fees AUD 5,500 (Category 2) to AUD 90,000 (Category 1 with full clinical review). These fees apply per ARTG entry -- a 500mg and a 1,000mg dose of the same product require separate ARTG entries and separate fees.

Timeline for a standard AUST L listed medicine with compliant documentation: ARTG entry within 5 to 10 business days. Total project timeline from start to lawful importation is 4 to 6 months factoring GMP Clearance processing (4 to 12 weeks), label compliance design (4 to 8 weeks), and sponsor establishment (2 to 4 weeks). Taiwan brands requiring faster market entry should prioritise product formulation to meet standard AUST L listing criteria rather than pursuing assessed listing.

Annual Charges are invoiced each October with a 28-day payment deadline. Unpaid charges result in automatic ARTG cancellation. For Taiwan exporters using Australian contract sponsors, non-payment by the sponsor makes your product unlawful to supply even when you have done everything correctly. Include Annual Charge confirmation obligations and audit rights in all sponsor agreements.

Budget for a Taiwan supplement brand entering Australia: initial listing application fees AUD 1,110 to 8,460 per product; GMP Clearance application AUD 16,280+; contract sponsor annual fee AUD 3,000 to 8,000; regulatory consultant pre-assessment AUD 3,000 to 8,000; Annual Charges AUD 1,110 per product per year ongoing. A brand listing 5 products should budget AUD 30,000 to 60,000 for Year 1 compliance infrastructure.

ARTG sponsors have ongoing post-market obligations under Part 4-8 of the Therapeutic Goods Act 1989. Serious adverse events must be reported to the TGA via the MedWatch Australia portal within 72 hours. Non-serious adverse events must be reported within 30 days. Taiwan brands must establish a pharmacovigilance system to capture reports from Australian distributors and consumers and route them to the TGA within statutory timeframes.

Product recall obligations apply when a therapeutic good presents a public health risk. The TGA publishes all recall notices publicly -- monitored by Australian pharmacies, hospitals, and retail buyers. Recall costs including consumer notification, product collection, and destruction are borne entirely by the sponsor. The TGA can issue Mandatory Recall orders with penalties for non-compliance of up to AUD 1.1 million per day.

Post-market audits are a significant compliance risk. The TGA selects ARTG entries for audit based on adverse event reports, consumer complaints, surveillance program test results, and overseas regulator intelligence. During audit, the TGA requests the full product dossier, evidence package, GMP certificates, batch testing records, and complaint logs within a tight deadline. Taiwan brands must maintain a complete audit-ready dossier for every ARTG entry at all times.

Annual Performance Reports (APR) must be submitted through TBS confirming Australian supply volumes, labelling changes, adverse events, and GMP currency. New Australia market entrants consistently underestimate post-market administrative burden -- budget 5 to 10 hours per ARTG entry per year for compliance maintenance including APR preparation, adverse event monitoring, and label change management.